12:00 AM
 | 
Jul 21, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Rhopressa: Phase III started

Aerie began the double-blind, U.S. Phase III Rocket 1 and Rocket 2 trials comparing 0.02% Rhopressa eye drops vs. twice-daily timolol in patients with glaucoma or ocular hypertension. Rocket 1 is evaluating once-daily Rhopressa...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >